mefloquine has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, DR; Bebbington, D; Benwell, K; Cliffe, IA; Dawson, CE; Dourish, CT; Fletcher, A; Gaur, S; Giles, PR; Gillespie, RJ; Jordan, AM; Knight, AR; Knutsen, LJ; Lawrence, A; Lerpiniere, J; Misra, A; Porter, RH; Pratt, RM; Shepherd, R; Upton, R; Ward, SE; Weiss, SM; Williamson, DS | 1 |
| Benwell, K; Cliffe, IA; Dourish, CT; Gillespie, RJ; Knight, AR; Lerpiniere, J; Misra, A; Pratt, RM; Revell, D; Upton, R; Weiss, SM | 1 |
2 other study(ies) available for mefloquine and Parkinsonian Disorders
| Article | Year |
|---|---|
Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives.
Topics: Adenosine A2 Receptor Antagonists; Antimalarials; Antiparkinson Agents; Humans; Models, Chemical; Parkinsonian Disorders; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2008 |
Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Binding, Competitive; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mefloquine; Mice; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Phenethylamines; Purines; Pyrimidines; Radioligand Assay; Rats; Triazines; Triazoles | 2003 |